Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - Histogen Inc. | d36524dex991.htm |
EX-10.2 - EX-10.2 - Histogen Inc. | d36524dex102.htm |
EX-10.1 - EX-10.1 - Histogen Inc. | d36524dex101.htm |
EX-4.2 - EX-4.2 - Histogen Inc. | d36524dex42.htm |
EX-4.1 - EX-4.1 - Histogen Inc. | d36524dex41.htm |
8-K - 8-K - Histogen Inc. | d36524d8k.htm |
Exhibit 5.1
DLA Piper LLP (US) 4365 Executive Drive, Suite 1100 San Diego, California 92121-2133 www.dlapiper.com
T 858.677.1400 F 858.677.1401 |
November 11, 2020
Histogen Inc.
10655 Sorrento Valley Road, Suite 200
San Diego, CA 92121
Ladies and Gentlemen:
You have requested our opinion with respect to certain matters in connection with the sale and issuance by Histogen Inc., a Delaware corporation (the Company), of up to an aggregate of 2,522,784 shares (the Shares) of the Companys common stock, par value $0.0001 per share (the Common Stock), pursuant to a Registration Statement on Form S-3 (File No. 333-248074) (the Registration Statement) filed with the Securities and Exchange Commission (the Commission) under the Securities Act of 1933, as amended (the Act), the related prospectus included therein (the Prospectus), and the prospectus supplement to be filed with the Commission pursuant to Rule 424(b) promulgated under the Act (the Prospectus Supplement).
In connection with this opinion, we have examined and relied upon the Registration Statement and the related Prospectus and Prospectus Supplement, the Companys Amended and Restated Certificate of Incorporation, as amended, and Amended and Restated Bylaws, as amended, as currently in effect, and the originals or copies certified to our satisfaction of such other documents, records, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below.
In rendering this opinion, we have assumed the genuineness and authenticity of all signatures on original documents; the genuineness and authenticity of all documents submitted to us as originals; the conformity to originals of all documents submitted to us as copies; the accuracy, completeness and authenticity of certificates of public officials; and the due authorization, execution and delivery of all documents where due authorization, execution and delivery are prerequisites to the effectiveness of such documents (other than with respect to the Company).
On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares have been duly and validly authorized and, when issued and sold pursuant to that certain securities purchase agreement, by and between the Company and the investors named therein, dated November 11, 2020, and in accordance with the Registration Statement and the related Prospectus and Prospectus Supplement, will be validly issued, fully paid and nonassessable.
We consent to the reference to our firm under the caption Legal Matters in the Prospectus Supplement and to the filing of this opinion as an exhibit to a Current Report of the Company on Form 8-K. In giving our consent, we do not thereby admit that we are in the category of persons
1
Page Two
whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder.
Very truly yours, |
/s/ DLA Piper LLP (US) |
DLA PIPER LLP (US) |
LN
2